Search
for
Sort by
Research 481–510 of 1000+
- Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
- Emerging treatments in alopecia
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment
- Review of modern methods of treating vitiligo
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Successful treatment of alopecia totalis with tofacitinib in a Danish patient
- Treatment of alopecia areata with JAK inhibitors
- Komplet remission ved behandling med JAK-hæmmer hos en patient med alopeciatotalis
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Platycladus orientalis Leaf Extract Promotes Hair Growth via Non-Receptor Tyrosine Kinase ACK1 Activation
- Alopecia areata: recognition, diagnosis and management
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Ritlecitinib: First Approval
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Review of Baricitinib in the Treatment of Alopecia Areata.